RCEL vs. ANGO, UTMD, TLSI, INO, SGHT, PROF, GUTS, OBIO, CVRX, and ARAY
Should you be buying AVITA Medical stock or one of its competitors? The main competitors of AVITA Medical include AngioDynamics (ANGO), Utah Medical Products (UTMD), TriSalus Life Sciences (TLSI), Inovio Pharmaceuticals (INO), Sight Sciences (SGHT), Profound Medical (PROF), Fractyl Health (GUTS), Orchestra BioMed (OBIO), CVRx (CVRX), and Accuray (ARAY). These companies are all part of the "surgical & medical instruments" industry.
AVITA Medical (NASDAQ:RCEL) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
AngioDynamics received 288 more outperform votes than AVITA Medical when rated by MarketBeat users. However, 68.22% of users gave AVITA Medical an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
AVITA Medical has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.
27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 1.8% of AVITA Medical shares are held by insiders. Comparatively, 5.1% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
AngioDynamics has a net margin of -60.21% compared to AVITA Medical's net margin of -70.56%. AngioDynamics' return on equity of -3.48% beat AVITA Medical's return on equity.
AVITA Medical has higher earnings, but lower revenue than AngioDynamics. AVITA Medical is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
AVITA Medical currently has a consensus price target of $24.60, indicating a potential upside of 196.39%. AngioDynamics has a consensus price target of $14.25, indicating a potential upside of 131.71%. Given AVITA Medical's higher probable upside, research analysts clearly believe AVITA Medical is more favorable than AngioDynamics.
In the previous week, AVITA Medical had 11 more articles in the media than AngioDynamics. MarketBeat recorded 13 mentions for AVITA Medical and 2 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.88 beat AVITA Medical's score of -0.03 indicating that AngioDynamics is being referred to more favorably in the news media.
Summary
AngioDynamics beats AVITA Medical on 11 of the 18 factors compared between the two stocks.
Get AVITA Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AVITA Medical Competitors List
Related Companies and Tools
